Adult hemodialysis patients: A prospective study on the use of intravenous L-carnitine

Creative Commons License

Yazar H., Kayhan B. C., Basarali K. M., Balci M.

AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, vol.5, no.11, pp.1349-1352, 2011 (SCI-Expanded) identifier identifier


The use of L-carnitine is very popular in recent years, but because of the lack of clinical trials, they are still sufficiently descriptive, and thus remain a mystery. However, a very common complication in hemodialysis patients is caused by a decrease in the serious incidence put forward by recent studies. This study aims to show if there are common reduced complications in patients using L-carnitine. All the patients treated in our center, and who were included in this study and in each session (three sessions per week for at least four hours of receiving treatment), comprised adults. The assessment of hepatitis B virus and hepatitis C virus (HBS-HCV) positive patients in the infectious diseases specialist took an active part of this study. Our unit of L-carnitine application did not meet our criteria, except a few exceptions, where all patients 3/7 were 1 g IV. The excessive risk group of patients with high blood pressure arterial, in terms of intra-oculer bleeding, were evaluated by a specialist in eye diseases. In this evaluation, dialysis dose adjustments used in the treatment of heparin were taken into consideration. According to the guideline study, some of the incidence of complications are: Hypotension, muscle cramp, restless leg syndrome, nausea and vomiting, headache, chest and back pain, itching and chills and fever. For L-carnitine used in our center during the 12-month period in patients with complications, an average reduction was seen in densities and growth rates of the guideline study according to the following figures: 20% reduction in the incidence of hypotension, 36% reduction in the incidence of muscle cramps, 50% reduction in the incidence of restless leg syndrome, 100% reduction in the incidence of nausea and vomiting, 100% reduction in the incidence of chest and back pain, no change was seen in headache and chills and fever complications, while an increase of 40% was observed for itching. In this study, no change was observed in headache and chills and fever symptoms; although aside itching, all other complications reduced. In patients, itching was examined at the front of those people diagnosed with familial Mediterranean fever (FMF) and in elderly people, and it was concluded that the situation may be a factor for the increase in complications.